Jyong Biotech Ltd. Ordinary Shares (MENS) is a publicly traded Healthcare sector company. As of July 26, 2026, MENS trades at $2.38 with a market cap of $175.19M and a P/E ratio of 0.00. MENS moved -11.99% today. Year to date, MENS is -40.25%; over the trailing twelve months it is -79.97%. Its 52-week range spans $1.43 to $67.00. Rallies surfaces MENS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jyong Biotech Showcases Botreso® After Four Phase III Trials, Accelerates NDA Prep: Jyong Biotech presented its botanical drug candidate Botreso® at BIO 2026, highlighting completion of four Phase III trials in the US and Taiwan for BPH and LUTS. The company is accelerating NDA preparations and engaging potential partners for regional licensing in the US, Europe and Asia to accelerate commercialization.
| Metric | Value |
|---|---|
| Price | $2.38 |
| Market Cap | $175.19M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $67.00 |
| 52-Week Low | $1.43 |
| Volume | 57.05K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
MENS analyst coverage data. Average price target: $0.00.